Despite great advances in cardiovascular biology and medical therapy, CVDs remain the major cause of mortality and morbidity worldwide and have consistently been an important public health issue. Extracellular vesicles have attracted much attention in mediating intercellular communication during cardiovascular development and pathophysiology. Exosomal ncRNAs, including microRNAs, lncRNAs and circRNAs, are considered to be key players, offering a potential source of novel diagnostic and prognostic biomarkers for CVDs. Especially, stem cell-derived exosomes have a great potential as a novel alternative to cell therapies in cardiovascular disease owing to their biocompatibility and non-immunogenicity. However, hurdles regarding exosome purification, batch difference, dosage and untargeted delivery need to be overcome in preclinical and clinical practice.
This Research Topic aims to highlight the novel studies and strategies that might overcome current obstacles in cardiovascular translational medicine and their potential applications. Original research and review articles are welcome.
Specific themes we would like contributors to address include, but are not limited to:
1) Extracellular vesicles in differentiation of cardiovascular cells.
2) Extracellular vesicles in cardiovascular repair.
3) Extracellular vesicles in cardiovascular protection.
4) Extracellular vesicles in cardiovascular drug development and safety assay.
5) Extracellular vesicles in tissue engineering.
6) Extracellular vesicles in CVD diagnostic and prognostic.
7) Extracellular vesicles in CVD pathogenesis.
8) Extracellular vesicles in cardiovascular homeostasis.
Despite great advances in cardiovascular biology and medical therapy, CVDs remain the major cause of mortality and morbidity worldwide and have consistently been an important public health issue. Extracellular vesicles have attracted much attention in mediating intercellular communication during cardiovascular development and pathophysiology. Exosomal ncRNAs, including microRNAs, lncRNAs and circRNAs, are considered to be key players, offering a potential source of novel diagnostic and prognostic biomarkers for CVDs. Especially, stem cell-derived exosomes have a great potential as a novel alternative to cell therapies in cardiovascular disease owing to their biocompatibility and non-immunogenicity. However, hurdles regarding exosome purification, batch difference, dosage and untargeted delivery need to be overcome in preclinical and clinical practice.
This Research Topic aims to highlight the novel studies and strategies that might overcome current obstacles in cardiovascular translational medicine and their potential applications. Original research and review articles are welcome.
Specific themes we would like contributors to address include, but are not limited to:
1) Extracellular vesicles in differentiation of cardiovascular cells.
2) Extracellular vesicles in cardiovascular repair.
3) Extracellular vesicles in cardiovascular protection.
4) Extracellular vesicles in cardiovascular drug development and safety assay.
5) Extracellular vesicles in tissue engineering.
6) Extracellular vesicles in CVD diagnostic and prognostic.
7) Extracellular vesicles in CVD pathogenesis.
8) Extracellular vesicles in cardiovascular homeostasis.